Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Lianyungang Runzhong Pharmaceutical Co., Ltd.

Centaurus Biopharma Co., Ltd.

Centaurus Biophrama Co., Ltd.

Shouyao Holdings Co., Ltd.

Xiaowei Duan

Liguang Dai

Li Zhu

Yong Peng

Yongxin Han

Yuandong Hu

Shanchun Wang

Yanqing Yang

Ling Yang

Yinghui Sun

Fansheng Kong

Hui Zhang

Hong Luo

Rui Zhao

Xin Tian

Zhao Yang

Wei Wu

Hongjiang Xu

Na Zhao

Fei Liu

Dengming Xiao

Xijie Liu

Ying Sun

Yizhong Zhu

Chang Lu

Meng Guo

Hongjuan Li

Zhaobai Zhong

Jiuqing Zhang

Yeling Ji

Nan Jiao

Deng Hou

Jinsuo Yao

Wangyang Min

Baokun Yuan

An iridinesulfonamide compound having isocitrate dehydrogenase 1 (IDH1) inhibitory activity, pharmaceutically acceptable salts, solvates or hydrates thereof, a pharmaceutical composition, as well as use of the compound or the pharmaceutically acceptable salts, solvates or hydrates thereof, and the pharmaceutical composition thereof in treating IDH1 mutation induced cancer. 

Iridinesulfonamide compound and use method thereof

Provided are a sultam compound having isocitrate dehydrogenase 1 (IDH1) inhibitory activity as represented by formula I or pharmaceutically-acceptable salts, solvates or hydrates thereof, a preparation method thereof, and a pharmaceutical composition containing the compound. The compound or the pharmaceutically-acceptable salts, solvates or hydrates thereof, and the pharmaceutical composition containing the compound can be used to treat IDH1 mutation-induced cancers. 

Sultam compound and application method thereof

The present application relates to a macrocycle containing aminopyrazole and pyrimidine, which is represented by formula (I), a pharmaceutical composition thereof, and a use thereof in inhibiting tropomyosin receptor kinase (Trk) activity and in treating diseases in mammals that are mediated by Trk. 

Macrocycle containing aminopyrazole and pyrimidine and pharmaceutical composition and use thereof

Provided is an amino pyrazolopyrimidine compound as represented by the following structural formula used as a neurotrophic factor tyrosine kinase receptor inhibitor. The compound can inhibit the activity of Trk kinase and can treat diseases mediated by a Trk tyrosine kinase receptor in mammals. 

Amino pyrazolopyrimidine compound used as neurotrophic factor tyrosine kinase receptor inhibitor

The present application relates to the field of pharmaceutical chemistry, and in particular, to a pyrrolopyrimidine compound represented by general formula (I), a stereoisomer thereof, or a pharmaceutically acceptable salt thereof. The present invention further relates to a method for preparing the pyrrolopyrimidine compound represented by general formula (I), pharmaceutical compositions and an application of the pyrrolopyrimidine compound in treating diseases mediated by Janus Kinase. 

Pyrrolopyrimidine compound

Growing community of inventors

Beijing, China

Xiaowei Duan